NasdaqCM - Delayed Quote USD

Aadi Bioscience, Inc. (AADI)

1.8800 +0.0400 (+2.17%)
At close: May 28 at 4:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
23,840.0000
24,354.0000
15,216.0000
1,000.0000
14,000.0000
Cost of Revenue
2,932.0000
2,809.0000
1,335.0000
--
--
Gross Profit
20,908.0000
21,545.0000
13,881.0000
1,000.0000
--
Operating Expense
95,528.0000
93,478.0000
72,838.0000
38,061.0000
16,549.0000
Operating Income
-74,620.0000
-71,933.0000
-58,957.0000
-37,061.0000
-2,549.0000
Net Non Operating Interest Income Expense
5,791.0000
6,169.0000
2,168.0000
-652.0000
-774.0000
Other Income Expense
--
-1.0000
-3,724.0000
-72,375.0000
-153.0000
Pretax Income
-68,831.0000
-65,765.0000
-60,513.0000
-110,088.0000
-3,476.0000
Tax Provision
--
--
--
2.0000
2.0000
Net Income Common Stockholders
-68,831.0000
-65,765.0000
-60,513.0000
-110,737.0000
-4,465.0000
Diluted NI Available to Com Stockholders
-68,831.0000
-65,765.0000
-60,513.0000
-110,737.0000
-4,465.0000
Basic EPS
-2.55
-2.44
-2.69
-12.41
-0.21
Diluted EPS
-2.55
-2.44
-2.69
-12.41
-0.21
Basic Average Shares
26,947.4800
26,917.9670
22,511.2370
8,923.3690
20,838.2920
Diluted Average Shares
26,947.4800
26,917.9670
22,511.2370
8,923.3690
20,838.2920
Total Operating Income as Reported
-74,620.0000
-71,933.0000
-62,681.0000
-111,217.0000
-2,549.0000
Total Expenses
98,460.0000
96,287.0000
74,173.0000
38,061.0000
16,549.0000
Net Income from Continuing & Discontinued Operation
-68,831.0000
-65,765.0000
-60,513.0000
-110,090.0000
-3,478.0000
Normalized Income
-68,829.0000
-65,764.0000
-56,789.0000
-56,099.2000
-3,478.0000
Interest Income
6,022.0000
6,400.0000
2,398.0000
13.0000
41.0000
Interest Expense
231.0000
231.0000
230.0000
665.0000
815.0000
Net Interest Income
5,791.0000
6,169.0000
2,168.0000
-652.0000
-774.0000
EBIT
-68,600.0000
-65,534.0000
-60,283.0000
-109,423.0000
-2,661.0000
EBITDA
-68,419.0000
-65,365.0000
-60,124.0000
-109,318.0000
-2,652.0000
Reconciled Cost of Revenue
2,932.0000
2,809.0000
1,335.0000
--
--
Reconciled Depreciation
181.0000
169.0000
159.0000
105.0000
9.0000
Net Income from Continuing Operation Net Minority Interest
-68,831.0000
-65,765.0000
-60,513.0000
-110,090.0000
-3,478.0000
Total Unusual Items Excluding Goodwill
-2.0000
-1.0000
-3,724.0000
-73,960.0000
--
Total Unusual Items
-2.0000
-1.0000
-3,724.0000
-73,960.0000
--
Normalized EBITDA
-68,417.0000
-65,364.0000
-56,400.0000
-35,358.0000
-2,652.0000
Tax Rate for Calcs
--
--
--
0.0003
0.0003
Tax Effect of Unusual Items
--
--
--
-19,969.2000
--
12/31/2020 - 2/16/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PMVP PMV Pharmaceuticals, Inc.
2.0100
-1.47%
 
IMRX Immuneering Corporation
1.4400
+3.60%
 
ANTX AN2 Therapeutics, Inc.
2.1200
+4.95%
 
AVBP ArriVent BioPharma, Inc.
18.97
-1.40%
 
BOLD Boundless Bio, Inc.
9.60
-15.12%
 
IKNA Ikena Oncology, Inc.
1.3300
0.00%
 
LUMO Lumos Pharma, Inc.
2.3100
-5.71%
 
ALDX Aldeyra Therapeutics, Inc.
3.7900
-3.07%
 
ACXP Acurx Pharmaceuticals, Inc.
2.5100
0.00%
 
BNTC Benitec Biopharma Inc.
8.55
-7.07%